サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1797404

エピジェネティクスの世界市場：製品・サービス別、手法別、技法別、用途別、エンドユーザー別 - 予測（～2030年）

Epigenetics Market by Product & Service (Enzymes, Kits & Reagents, Software), Method, Technique, Application, End User - Global Forecast to 2030

出版日
ページ情報
英文 491 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
エピジェネティクスの世界市場：製品・サービス別、手法別、技法別、用途別、エンドユーザー別 - 予測（～2030年）
出版日: 2025年08月15日
発行: MarketsandMarkets
ページ情報: 英文 491 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のエピジェネティクスの市場規模は、2025年の22億4,000万米ドルから2030年までに42億9,000万米ドルに達すると予測され、予測期間にCAGRで13.9%の成長が見込まれます。

調査範囲
調査対象年 2024年～2033年
基準年 2024年
予測期間 2025年～2030年
単位 10億米ドル
セグメント 提供、手法、技法、用途、エンドユーザー（製品）、エンドユーザー（サービス）、地域
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

エピジェネティクスの技術的進歩、エピジェネティック薬や診断に対する需要の高まりとともに、シーケンシングコストや時間の減少といった要因が市場成長を後押ししています。しかし、毒性学におけるエピゲノムデータの用途が限られていることや、データプライバシーやセキュリティ上の懸念により、市場の拡大は抑制されています。

Epigenetics Market-IMG1

「PCR・qPCR市場がより速いペースで成長する可能性が高いです。」

メチル化特異的PCR技術の活用の向上が、後成的修飾を検出する感度と特異性を高め、このセグメントの成長を促進すると予測されます。

「DNAメチル化が手法セグメントを独占しました。」

2024年、DNAメチル化が市場を独占しました。がん研究用途における確立された有効性がその主因です。さらに、ノンコーディングRNA解析やクロマチンリモデリングを含む代替の手法が、予測期間を通じてもっとも高いCAGRを示す見込みです。これは、革新的なエピジェネティックメカニズムと、診断と治療開発におけるその将来的な役割に対する注目の高まりによるものです。

「アジア太平洋がもっとも速い成長率を示すと推定されます。」

2024年、北米がエピジェネティクス市場のシェアの大部分を占めています。アジア太平洋は、新興経済圏全体の医療インフラの継続的な向上により、予測期間に力強く成長する見込みです。この市場は、地域の業界参入企業によって開始された戦略的提携、パートナーシップ、拡張、合意によってさらに後押しされています。

当レポートでは、世界のエピジェネティクス市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要な知見

  • エピジェネティクス市場の概要
  • 北米のエピジェネティクス市場：技法別
  • エピジェネティクス製品市場：エンドユーザー別（2024年）
  • エピジェネティクス市場：地理的成長機会

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • カスタマービジネスに影響を与える動向/混乱
  • 価格設定の分析
    • 平均販売価格の動向：主要企業別
    • 平均販売価格の動向：地域別
  • バリューチェーン分析
  • エコシステム分析
  • 投資と資金調達のシナリオ
  • 技術分析
    • 主要技術
    • 補完技術
  • 特許分析
  • 貿易データアナリティクス
    • 輸入データ
    • 輸出データ
  • 主な会議とイベント（2025年～2026年）
  • 関税と規制情勢
    • HSコード9027.50.80と3822.00の関税データ
    • 規制枠組み
    • 規制機関、政府機関、その他の組織
  • ポーターのファイブフォース分析
  • 主なステークホルダーと購入基準
  • エピジェネティクス市場に対するAI/生成AIの影響
    • イントロダクション
    • エピジェネティクスにおけるAIの市場の将来性
    • AIユースケース
    • AI/生成AIを導入している主要企業
    • エピジェネティクス市場におけるAI/生成AIの未来
  • 2025年の米国関税の影響
    • イントロダクション
    • 主な関税率
    • 価格の影響の分析
    • さまざまな地域への主な影響
    • 最終用途産業に対する影響

第6章 エピジェネティクス市場：提供別

  • イントロダクション
  • キット・試薬
  • 酵素
  • 器具・アクセサリ
  • ソフトウェア
  • サービス

第7章 エピジェネティクス市場：技法別

  • イントロダクション
  • 次世代シーケンシング（NGS）
  • PCR・qPCR
  • 質量分析
  • 超音波処理
  • その他の技法

第8章 エピジェネティクス市場：手法別

  • イントロダクション
  • DNAメチル化
  • ヒストン修飾
  • その他の手法

第9章 エピジェネティクス市場：用途別

  • イントロダクション
  • 腫瘍学
  • 代謝性疾患
  • 免疫学
  • 発生生物学
  • 心血管疾患
  • その他の用途

第10章 エピジェネティクス製品市場：エンドユーザー別

  • イントロダクション
  • 学術・研究機関
  • 製薬・バイオテクノロジー企業
  • 病院・診療所
  • 開発業務受託機関

第11章 エピジェネティクスサービス市場：エンドユーザー別

  • イントロダクション
  • 製薬・バイオテクノロジー企業
  • 学術・研究機関
  • 病院・診療所

第12章 エピジェネティクス市場：地域別

  • イントロダクション
  • 北米
    • 北米のマクロ経済の見通し
    • 米国
    • カナダ
  • 欧州
    • 欧州のマクロ経済の見通し
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • アジア太平洋のマクロ経済の見通し
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
    • ラテンアメリカのマクロ経済の見通し
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
  • 中東
    • 中東のマクロ経済の見通し
    • GCC諸国
    • その他の中東
  • アフリカ

第13章 競合情勢

  • イントロダクション
  • 主要参入企業の戦略
  • 収益分析
  • 市場シェア分析
  • 企業の評価と財務指標
  • ブランド/製品の比較
    • THERMO FISHER SCIENTIFIC INC.
    • ILLUMINA, INC.
    • MERCK KGAA
    • DANAHER
  • 企業の評価マトリクス：主要企業（2024年）
  • 企業の評価マトリクス：スタートアップ/中小企業（2024年）
  • 競合シナリオ

第14章 企業プロファイル

  • KEY MARKET PLAYERS
    • THERMO FISHER SCIENTIFIC INC.
    • ILLUMINA, INC.
    • MERCK KGAA
    • PACBIO
    • DANAHER
    • BIO-RAD LABORATORIES, INC.
    • ACTIVE MOTIF
    • NEW ENGLAND BIOLABS
    • QIAGEN
    • ZYMO RESEARCH CORPORATION
    • REVVITY
    • HOLOGIC, INC.
    • F. HOFFMANN-LA ROCHE LTD
    • PROMEGA CORPORATION
    • EPIGENTEK GROUP INC.
  • その他の企業
    • EPICYPHER
    • FIOS GENOMICS
    • GENOMESCAN
    • CREATIVE BIOGENE
    • BPS BIOSCIENCE, INC.
    • ABNOVA CORPORATION
    • CREATIVE DIAGNOSTICS
    • BIOMODAL
    • INTEGRATED DNA TECHNOLOGIES, INC.
    • NOVOGENE CO., LTD.

第15章 付録

図表

List of Tables

  • TABLE 1 EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 3 EPIGENETICS MARKET: RISK ANALYSIS
  • TABLE 4 EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 AVERAGE SELLING PRICE TREND OF EPIGENETIC PRODUCTS, BY KEY PLAYER, 2022-2024 (USD MILLION)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2022-2024 (USD MILLION)
  • TABLE 7 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS AND REAGENTS, BY REGION, 2022-2024 (USD MILLION)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF EPIGENETIC ENZYMES, BY REGION, 2022-2024 (USD MILLION)
  • TABLE 9 EPIGENETICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 10 EPIGENETICS MARKET: INVESTMENT AND FUNDING SCENARIO OF KEY PLAYERS, 2022-2025
  • TABLE 11 EPIGENETICS MARKET: PATENTS FILED GLOBALLY, 2014-2024
  • TABLE 12 EPIGENETICS MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2024-2025
  • TABLE 13 IMPORT VALUE OF HS CODE 9027.50- COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (USD THOUSAND)
  • TABLE 14 IMPORT VALUE OF HS CODE 382.00- COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (USD THOUSAND)
  • TABLE 15 EXPORT VALUE OF HS CODE 9027.50 - COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (USD THOUSAND)
  • TABLE 16 EXPORT VALUE OF HS CODE 3822.00 - COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (USD THOUSAND)
  • TABLE 17 EPIGENETICS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 18 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00
  • TABLE 19 KEY REGULATORY AGENCIES
  • TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 EPIGENETICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • TABLE 28 KEY BUYING CRITERIA, BY END USER
  • TABLE 29 LIST OF COMPANIES IMPLEMENTING AI/GEN AI IN EPIGENETICS MARKET
  • TABLE 30 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 31 EXPORTS AND IMPORTS, BY REGION, 2024-2025
  • TABLE 32 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO EPIGENETICS
  • TABLE 33 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
  • TABLE 34 EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 35 EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 36 EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 37 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 49 GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 72 NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 77 GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 EPIGENETICS MARKET FOR HISTONES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 79 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 84 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 91 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 93 EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 99 GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 100 EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 EUROPE: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 MIDDLE EAST: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 106 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 107 EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 113 GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 120 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 122 NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 127 GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 EPIGENETICS MARKET FOR SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 129 NORTH AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 130 EUROPE: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 LATIN AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 MIDDLE EAST: EPIGENETICS MARKET FOR SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 134 REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 EPIGENETICS MARKET FOR SERVICES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 136 NORTH AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 137 EUROPE: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 139 LATIN AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 MIDDLE EAST: EPIGENETICS MARKET FOR SERVICES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 141 GCC COUNTRIES: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 142 EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 143 EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 149 GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 151 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 156 GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 158 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 159 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 161 LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 163 GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 165 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 166 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 168 LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 170 GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 171 EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 172 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 173 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 175 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 176 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 177 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 178 EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 179 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 180 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 183 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 184 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
  • TABLE 187 EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 188 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 189 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 190 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 191 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 192 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 193 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 194 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 195 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 196 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 197 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 198 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 199 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 200 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 201 EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 202 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS
  • TABLE 203 EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 204 NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 205 EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 207 LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 208 MIDDLE EAST: EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 209 GCC COUNTRIES: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 210 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 211 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 212 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 214 LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 215 MIDDLE EAST: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 216 GCC COUNTRIES: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 217 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 218 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 219 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 221 LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 222 MIDDLE EAST: EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 223 GCC COUNTRIES: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 224 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 225 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 226 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 228 LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 229 MIDDLE EAST: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 230 GCC COUNTRIES: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 231 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 232 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 233 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 235 LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 236 MIDDLE EAST: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 237 GCC COUNTRIES: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 238 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 239 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 240 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 242 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 243 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 244 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 245 EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 246 EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 247 NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 248 EUROPE: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 249 ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 250 LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 251 MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 252 GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 253 EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 254 NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 255 EUROPE: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 257 LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 258 MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 260 EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 261 NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 262 EUROPE: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 263 ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 264 LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 265 MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 266 GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 267 EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 268 NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 269 EUROPE: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 270 ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 271 LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 272 MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 273 GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 274 EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 275 EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 276 NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 277 EUROPE: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 278 ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 279 LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 280 MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 281 GCC COUNTRIES: EPIGENETICS SERVICE MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 282 EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 283 NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 284 EUROPE: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 285 ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 286 LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 287 MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 288 GCC COUNTRIES: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 289 EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 290 NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 291 EUROPE: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 292 ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 293 LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 294 MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 295 GCC COUNTRIES: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 296 EPIGENETICS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 297 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 298 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 299 NORTH AMERICA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 300 NORTH AMERICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 301 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 302 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 303 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 304 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 305 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 306 NORTH AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 307 NORTH AMERICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 308 US: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 309 US: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 310 US: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 311 US: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 312 US: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 313 US: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 314 US: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 315 US: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 316 US: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 317 CANADA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 318 CANADA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 319 CANADA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 CANADA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 321 CANADA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 322 CANADA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 323 CANADA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 324 CANADA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 325 CANADA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 326 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 327 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 328 EUROPE: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 329 EUROPE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 330 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 331 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 332 EUROPE: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 333 EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 334 EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 335 EUROPE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 336 EUROPE: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 337 GERMANY: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 338 GERMANY: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 339 GERMANY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 340 GERMANY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 341 GERMANY: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 342 GERMANY: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 343 GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 344 GERMANY: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 345 GERMANY: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 346 UK: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 347 UK: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 348 UK: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 349 UK: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 350 UK: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 351 UK: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 352 UK: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 353 UK: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 354 UK: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 355 FRANCE: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 356 FRANCE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 357 FRANCE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 358 FRANCE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 359 FRANCE: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 360 FRANCE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 361 FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 362 FRANCE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 363 FRANCE: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 364 ITALY: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 365 ITALY: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 366 ITALY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 367 ITALY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 368 ITALY: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 369 ITALY: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 370 ITALY: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 371 ITALY: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 372 ITALY: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 373 SPAIN: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 374 SPAIN: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 375 SPAIN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 376 SPAIN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 377 SPAIN: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 378 SPAIN: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 379 SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 380 SPAIN: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 381 SPAIN: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 382 REST OF EUROPE: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 383 REST OF EUROPE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 384 REST OF EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 385 REST OF EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 386 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 387 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 388 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 389 REST OF EUROPE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 390 REST OF EUROPE: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 391 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 392 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 393 ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 394 ASIA PACIFIC: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 395 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 396 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 397 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 398 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 399 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 400 ASIA PACIFIC: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 401 ASIA PACIFIC: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 402 CHINA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 403 CHINA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 404 CHINA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 405 CHINA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 406 CHINA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 407 CHINA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 408 CHINA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 409 CHINA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 410 CHINA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 411 JAPAN: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 412 JAPAN: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 413 JAPAN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 414 JAPAN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 415 JAPAN: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 416 JAPAN: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 417 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 418 JAPAN: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 419 JAPAN: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 420 INDIA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 421 INDIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 422 INDIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 423 INDIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 424 INDIA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 425 INDIA: EPIGENETICS MARKET, BY TECHNOLOGY 2023-2030 (USD MILLION)
  • TABLE 426 INDIA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 427 INDIA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 428 INDIA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 429 AUSTRALIA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 430 AUSTRALIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 431 AUSTRALIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 432 AUSTRALIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 433 AUSTRALIA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 434 AUSTRALIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 435 AUSTRALIA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 436 AUSTRALIA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 437 AUSTRALIA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 438 SOUTH KOREA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 439 SOUTH KOREA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 440 SOUTH KOREA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 441 SOUTH KOREA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 442 SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 443 SOUTH KOREA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 444 SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 445 SOUTH KOREA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 446 SOUTH KOREA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 447 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 448 REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 449 REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 450 REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 451 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 452 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 453 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 454 REST OF ASIA PACIFIC: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 455 REST OF ASIA PACIFIC: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 456 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 457 LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 458 LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 459 LATIN AMERICA: EPIGENETICS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 460 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 461 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 462 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 463 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 464 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 465 LATIN AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 466 LATIN AMERICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 467 BRAZIL: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 468 BRAZIL: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 469 BRAZIL: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 470 BRAZIL: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 471 BRAZIL: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 472 BRAZIL: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 473 BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 474 BRAZIL: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 475 BRAZIL: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 476 MEXICO: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 477 MEXICO: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 478 MEXICO: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 479 MEXICO: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 480 MEXICO: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 481 MEXICO: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 482 MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 483 MEXICO: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 484 MEXICO: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 485 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 486 REST OF LATIN AMERICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 487 REST OF LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 488 REST OF LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 489 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 490 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 491 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 492 REST OF LATIN AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 493 REST OF LATIN AMERICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 494 MIDDLE EAST: KEY MACROECONOMIC INDICATORS
  • TABLE 495 MIDDLE EAST: EPIGENETICS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 496 MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 497 MIDDLE EAST: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 498 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 499 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 500 MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 501 MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 502 MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 503 MIDDLE EAST: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 504 MIDDLE EAST: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 505 GCC COUNTRIES: EPIGENETICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 506 GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 507 GCC COUNTRIES: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 508 GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 509 GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 510 GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 511 GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 512 GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 513 GCC COUNTRIES: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 514 GCC COUNTRIES: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 515 SAUDI ARABIA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 516 SAUDI ARABIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 517 SAUDI ARABIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 518 SAUDI ARABIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 519 SAUDI ARABIA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 520 SAUDI ARABIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 521 SAUDI ARABIA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 522 SAUDI ARABIA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 523 SAUDI ARABIA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 524 UAE: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 525 UAE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 526 UAE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 527 UAE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 528 UAE: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 529 UAE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 530 UAE: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 531 UAE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 532 UAE: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 533 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 534 REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 535 REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 536 REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 537 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 538 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 539 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 540 REST OF GCC COUNTRIES: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 541 REST OF GCC COUNTRIES: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 542 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 543 REST OF MIDDLE EAST: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 544 REST OF MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 545 REST OF MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 546 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 547 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 548 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 549 REST OF MIDDLE EAST: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 550 REST OF MIDDLE EAST: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 551 AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 552 AFRICA: EPIGENETICS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 553 AFRICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 554 AFRICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 555 AFRICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 556 AFRICA: EPIGENETICS MARKET, BY METHOD, 2023-2030 (USD MILLION)
  • TABLE 557 AFRICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 558 AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 559 AFRICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 560 AFRICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 561 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, JANUARY 2022-JULY 2025
  • TABLE 562 EPIGENETICS MARKET: DEGREE OF COMPETITION
  • TABLE 563 EPIGENETICS MARKET: REGION FOOTPRINT
  • TABLE 564 EPIGENETICS MARKET: OFFERING FOOTPRINT
  • TABLE 565 EPIGENETICS MARKET: METHOD FOOTPRINT
  • TABLE 566 EPIGENETICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 567 EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 568 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 569 EPIGENETICS MARKET: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 570 EPIGENETICS MARKET: DEALS, JANUARY 2022-JULY 2025
  • TABLE 571 EPIGENETICS MARKET: OTHER DEVELOPMENTS, JANUARY 2022-JULY 2025
  • TABLE 572 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 573 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 574 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 575 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 576 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 577 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 578 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 579 ILLUMINA, INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 580 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 581 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 582 PACBIO: COMPANY OVERVIEW
  • TABLE 583 PACBIO: PRODUCTS OFFERED
  • TABLE 584 PACBIO: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 585 PACBIO: DEALS, JANUARY 2022-JULY 2025
  • TABLE 586 PACBIO: EXPANSIONS, JANUARY 2022- JULY 2025
  • TABLE 587 DANAHER: COMPANY OVERVIEW
  • TABLE 588 DANAHER: PRODUCTS OFFERED
  • TABLE 589 DANAHER: DEALS, JANUARY 2022-JULY 2025
  • TABLE 590 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 591 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 592 ACTIVE MOTIF: COMPANY OVERVIEW
  • TABLE 593 ACTIVE MOTIF: PRODUCTS OFFERED
  • TABLE 594 ACTIVE MOTIF: DEALS, JANUARY 2022-JULY 2025
  • TABLE 595 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 596 NEW ENGLAND BIOLABS: PRODUCTS OFFERED
  • TABLE 597 NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 598 NEW ENGLAND BIOLABS: DEALS, JANUARY 2022-JULY 2025
  • TABLE 599 QIAGEN: COMPANY OVERVIEW
  • TABLE 600 QIAGEN: PRODUCTS OFFERED
  • TABLE 601 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 602 ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW
  • TABLE 603 ZYMO RESEARCH CORPORATION: PRODUCTS OFFERED
  • TABLE 604 ZYMO RESEARCH CORPORATION: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 605 ZYMO RESEARCH CORPORATION: EXPANSIONS, JANUARY 2022-JULY 2025
  • TABLE 606 ZYMO RESEARCH CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022-JULY 2025
  • TABLE 607 REVVITY: COMPANY OVERVIEW
  • TABLE 608 REVVITY: PRODUCTS OFFERED
  • TABLE 609 REVVITY: DEALS, JANUARY 2022-JULY 2025
  • TABLE 610 HOLOGIC, INC. COMPANY OVERVIEW
  • TABLE 611 HOLOGIC, INC.: PRODUCTS OFFERED
  • TABLE 612 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 613 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 614 PROMEGA CORPORATION: COMPANY OVERVIEW
  • TABLE 615 PROMEGA CORPORATION: PRODUCTS OFFERED
  • TABLE 616 EPIGENTEK GROUP INC.: COMPANY OVERVIEW
  • TABLE 617 EPIGENTEK GROUP INC.: PRODUCTS OFFERED
  • TABLE 618 EPICYPHER: COMPANY OVERVIEW
  • TABLE 619 FIOS GENOMICS: COMPANY OVERVIEW
  • TABLE 620 GENOMESCAN: COMPANY OVERVIEW
  • TABLE 621 CREATIVE BIOGENE: COMPANY OVERVIEW
  • TABLE 622 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW
  • TABLE 623 ABNOVA CORPORATION: COMPANY OVERVIEW
  • TABLE 624 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 625 BIOMODAL: COMPANY OVERVIEW
  • TABLE 626 INTEGRATED DNA TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 627 NOVOGENE CO., LTD.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 EPIGENETICS MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 EPIGENETICS MARKET: YEARS CONSIDERED
  • FIGURE 3 EPIGENETICS MARKET: RESEARCH DESIGN
  • FIGURE 4 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 5 EPIGENETICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 6 EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2024
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS, 2024
  • FIGURE 8 EPIGENETICS MARKET: INSIGHTS FROM PRIMARY EXPERTS
  • FIGURE 9 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 10 EPIGENETICS MARKET: CAGR PROJECTIONS
  • FIGURE 11 EPIGENETICS MARKET: DATA TRIANGULATION
  • FIGURE 12 EPIGENETICS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 EPIGENETICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 EPIGENETICS MARKET, BY METHOD, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 EPIGENETICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 EPIGENETICS PRODUCT MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 EPIGENETICS SERVICE MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 GEOGRAPHIC ANALYSIS OF EPIGENETICS MARKET
  • FIGURE 19 TECHNOLOGICAL ADVANCEMENTS IN EPIGENETICS RESEARCH TO DRIVE MARKET GROWTH
  • FIGURE 20 DNA METHYLATION SEGMENT AND US LED NORTH AMERICAN EPIGENETICS MARKET IN 2024
  • FIGURE 21 ACADEMIC & RESEARCH INSTITUTES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 22 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL EPIGENETICS MARKET DURING FORECAST PERIOD
  • FIGURE 23 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001-2022
  • FIGURE 25 NUMBER OF CANCER CASES IN US, 2019-2024
  • FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN EPIGENETICS MARKET
  • FIGURE 27 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD)
  • FIGURE 28 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER, 2024 (USD)
  • FIGURE 29 AVERAGE SELLING PRICE OF ENZYMES, BY KEY PLAYER, 2024 (USD)
  • FIGURE 30 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION)
  • FIGURE 31 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY REGION, 2024 (USD MILLION)
  • FIGURE 32 AVERAGE SELLING PRICE OF ENZYMES, BY REGION, 2024 (USD MILLION)
  • FIGURE 33 EPIGENETICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 34 EPIGENETICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 35 EPIGENETICS MARKET: INVESTMENT AND FUNDING SCENARIO, 2022-2025
  • FIGURE 36 EPIGENETICS MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
  • FIGURE 37 EPIGENETICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 38 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • FIGURE 39 KEY BUYING CRITERIA, BY END USER
  • FIGURE 40 EPIGENETICS MARKET: AI USE CASES
  • FIGURE 41 EPIGENETICS MARKET, BY OFFERING, 2023-2030 (MILLION UNITS)
  • FIGURE 42 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
  • FIGURE 43 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
  • FIGURE 44 EPIGENETICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022-2024
  • FIGURE 45 EPIGENETICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 46 EV/EBITDA OF KEY VENDORS
  • FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 48 EPIGENETICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 49 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 50 EPIGENETICS MARKET: COMPANY FOOTPRINT
  • FIGURE 51 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 54 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 55 PACBIO: COMPANY SNAPSHOT (2024)
  • FIGURE 56 DANAHER: COMPANY SNAPSHOT (2024)
  • FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 QIAGEN: COMPANY SNAPSHOT (2024)
  • FIGURE 59 REVVITY: COMPANY SNAPSHOT (2024)
  • FIGURE 60 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 61 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
目次
Product Code: BT 2775

The global epigenetics market size is projected to reach USD 4.29 billion by 2030 from USD 2.24 billion in 2025, at a CAGR of 13.9% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2033
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsOffering, Method, Technology, Application, End User (Product), End User (Service), and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

Factors such as declining sequencing costs and time, along with technological advancements in epigenetics, and a growing demand for epigenetic drugs and diagnostics drive market growth; however, limited applications of epigenomic data in toxicology, along with data privacy and security concerns, restrain market expansion.

Epigenetics Market - IMG1

"The PCR & qPCR market is likely to grow at a faster pace."

The global epigenetics market is categorized by technology into next-generation sequencing (NGS), polymerase chain reaction (PCR) & quantitative PCR (qPCR), mass spectrometry, sonication, and other methodologies. Notably, the PCR & qPCR segment is projected to exhibit significant compound annual growth rate (CAGR). The rising utilization of methylation-specific PCR techniques enhances the sensitivity and specificity of detecting epigenetic modifications, which is anticipated to drive growth in this segment.

"DNA methylation dominated the method segment."

The epigenetics market is categorized by methodology into several segments, primarily DNA methylation, histone modifications, and other techniques. In 2024, DNA methylation dominated the market, primarily due to its established efficacy in cancer research applications. Furthermore, alternative methodologies-including non-coding RNA analysis and chromatin remodeling-are anticipated to exhibit the highest CAGR throughout the forecast period. This is driven by an increasing focus on innovative epigenetic mechanisms and their prospective roles in diagnostics and therapeutic development.

"Asia Pacific region is estimated to show fastest growth rate."

On the basis of region, the flow cytometry market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America accounted for the major share of the epigenetics market. The Asia Pacific region is projected to experience strong growth during the forecast period, fueled by ongoing improvements in healthcare infrastructure across emerging economies. This market is further boosted by strategic collaborations, partnerships, expansions, and agreements initiated by regional industry players.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
  • By Designation: Managers- 45%, CXOs and Directors- 30%, and Executives- 25%
  • By Region: North America -35%, Europe - 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific Inc. (US)
  • Merck KGaA (Germany)
  • Illumina, Inc. (US)
  • PacBio (US)
  • Danaher (US)
  • Active Motif, Inc. (US)
  • Bio-Rad Laboratories Inc. (US)
  • Promega Corporation (US)
  • Revvity (US)
  • Qiagen (Germany)
  • New England Biolabs (US)
  • Zymo Research Corporation (US)
  • Hologic Diagenode (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • EpiGentek Group Inc. (US)

Research Coverage:

This research report categorizes epigenetics market by offering (kits & reagents, enzymes, instruments & accessories, software, and services), method (DNA methylation, Histone modification, and other methods), technology (NGS, PCR & qPCR, mass spectrometry, sonication, and other technologies), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications), end user for product (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), end user for service (academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope includes detailed information about the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, solutions, and services; key strategies; new product and service launches, acquisitions, and recent developments related to the epigenetics market. This report also covers the competitive analysis of upcoming startups in the epigenetics industry ecosystem.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing estimates of revenue for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key Drivers (declining sequencing costs & time, expansion of population screening programs, technological advancements in epigenetics research, and rising demand for epigenetic drugs & epigenetics-based diagnostics), restraints (limited applications of epigenomic data in toxicology and data privacy concerns and security issues), opportunities (emerging applications of epigenetics and integration of multi-omics), and challenges (concerns regarding quality of antibodies and challenges associated with epigenetic editing) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the epigenetics market.
  • Market Development: The report provides comprehensive information about lucrative markets and analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), among others offering products and services for epigenetics market. Other companies include EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), among others, for the epigenetics market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 GLOBAL MARKET SIZE ESTIMATION
    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.3 SEGMENTAL MARKET ASSESSMENT
  • 2.3 GROWTH FORECAST MODEL
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 EPIGENETICS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY
  • 4.3 EPIGENETICS PRODUCT MARKET, BY END USER, 2024
  • 4.4 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Declining sequencing costs and time
      • 5.2.1.2 Growing emphasis on population-scale screening initiatives
      • 5.2.1.3 Technological advancements in epigenetics research
      • 5.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Limited applications of epigenomic data in toxicology
      • 5.2.2.2 Data privacy concerns and security issues
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging applications of epigenetics
      • 5.2.3.2 Integration of multi-omics
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Concerns regarding quality of antibodies
      • 5.2.4.2 Challenges associated with epigenetic editing
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 INVESTMENT AND FUNDING SCENARIO
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Single-cell sequencing
      • 5.8.1.2 Chromatin immunoprecipitation
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 DNA methylation microarrays
      • 5.8.2.2 CRISPR-based genome editing
  • 5.9 PATENT ANALYSIS
  • 5.10 TRADE DATA ANALYSIS
    • 5.10.1 IMPORT DATA
    • 5.10.2 EXPORT DATA
  • 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.12 TARIFF AND REGULATORY LANDSCAPE
    • 5.12.1 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00
    • 5.12.2 REGULATORY FRAMEWORK
    • 5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 BARGAINING POWER OF SUPPLIERS
    • 5.13.2 BARGAINING POWER OF BUYERS
    • 5.13.3 THREAT OF NEW ENTRANTS
    • 5.13.4 THREAT OF SUBSTITUTES
    • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 KEY BUYING CRITERIA
  • 5.15 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
    • 5.15.1 INTRODUCTION
    • 5.15.2 MARKET POTENTIAL OF AI IN EPIGENETICS
    • 5.15.3 AI USE CASES
    • 5.15.4 KEY COMPANIES IMPLEMENTING AI/GEN AI
    • 5.15.5 FUTURE OF AI/GEN AI IN EPIGENETICS MARKET
  • 5.16 IMPACT OF 2025 US TARIFF
    • 5.16.1 INTRODUCTION
    • 5.16.2 KEY TARIFF RATES
    • 5.16.3 PRICE IMPACT ANALYSIS
    • 5.16.4 KEY IMPACTS ON VARIOUS REGIONS
      • 5.16.4.1 US
      • 5.16.4.2 Europe
      • 5.16.4.3 Asia Pacific
    • 5.16.5 END-USE INDUSTRY IMPACT
      • 5.16.5.1 Pharmaceutical and biotech companies
      • 5.16.5.2 Contract Research Organizations (CROs)
      • 5.16.5.3 Academic and research institutes

6 EPIGENETICS MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 KITS & REAGENTS
    • 6.2.1 ANTIBODIES
      • 6.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market
    • 6.2.2 CHIP-SEQUENCING KITS & REAGENTS
      • 6.2.2.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market
    • 6.2.3 BISULFITE CONVERSION KITS & REAGENTS
      • 6.2.3.1 Effective outcomes associated with bisulfite conversion to sustain growth
    • 6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
      • 6.2.4.1 Ability to maintain relative proportions of genes in original pool to stimulate growth
    • 6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
      • 6.2.5.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth
    • 6.2.6 HISTONES
      • 6.2.6.1 Emerging importance of chromatin-associated proteins and histones in epigenetic research to bolster growth
    • 6.2.7 OTHER KITS & REAGENTS
  • 6.3 ENZYMES
    • 6.3.1 DNA-MODIFYING ENZYMES
      • 6.3.1.1 Broadening applications of DNA methylation to facilitate growth
    • 6.3.2 PROTEIN-MODIFYING ENZYMES
      • 6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to spur growth
    • 6.3.3 OTHER ENZYMES
  • 6.4 INSTRUMENTS & ACCESSORIES
    • 6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO EXPEDITE GROWTH
  • 6.5 SOFTWARE
    • 6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROMOTE GROWTH
  • 6.6 SERVICES
    • 6.6.1 EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE MARKET

7 EPIGENETICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 NEXT-GENERATION SEQUENCING (NGS)
    • 7.2.1 INCREASING LAUNCHES OF NEXT-GENERATION SEQUENCING PLATFORMS TO FACILITATE GROWTH
  • 7.3 PCR & QPCR
    • 7.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET
  • 7.4 MASS SPECTROMETRY
    • 7.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET
  • 7.5 SONICATION
    • 7.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO EXPEDITE GROWTH
  • 7.6 OTHER TECHNOLOGIES

8 EPIGENETICS MARKET, BY METHOD

  • 8.1 INTRODUCTION
  • 8.2 DNA METHYLATION
    • 8.2.1 INCREASING RESEARCH & DEVELOPMENT ACTIVITIES TO SPUR GROWTH
  • 8.3 HISTONE MODIFICATIONS
    • 8.3.1 GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • 8.4 OTHER METHODS

9 EPIGENETICS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 ONCOLOGY
    • 9.2.1 GROWING INVESTMENT IN EPIGENETIC-BASED RESEARCH TO BOOST MARKET
  • 9.3 METABOLIC DISEASES
    • 9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR GROWTH
  • 9.4 IMMUNOLOGY
    • 9.4.1 GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE MARKET
  • 9.5 DEVELOPMENTAL BIOLOGY
    • 9.5.1 INCREASING RESEARCH ON CELL GROWTH AND DIFFERENTIATION TO PROPEL MARKET
  • 9.6 CARDIOVASCULAR DISEASES
    • 9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO AID GROWTH
  • 9.7 OTHER APPLICATIONS

10 EPIGENETICS PRODUCTS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 ACADEMIC & RESEARCH INSTITUTES
    • 10.2.1 INCREASING PUBLIC-PRIVATE COLLABORATIONS TO FAVOR GROWTH
  • 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETIC-BASED DRUGS TO FUEL MARKET
  • 10.4 HOSPITALS & CLINICS
    • 10.4.1 GROWING USE OF PERSONALIZED MEDICINE TO PROPEL MARKET
  • 10.5 CONTRACT RESEARCH ORGANIZATIONS
    • 10.5.1 INCREASING DEMAND FOR SCALABLE, HIGH-THROUGHPUT EPIGENETICS KITS TO PROMOTE GROWTH

11 EPIGENETICS SERVICE MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 RISING DEMAND FOR THERAPEUTIC DISCOVERIES TO BOLSTER GROWTH
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH
  • 11.4 HOSPITALS & CLINICS
    • 11.4.1 INCREASING INTEGRATION OF EPIGENETIC ASSAYS INTO CLINICAL DIAGNOSTICS, PROGNOSTICS, AND PERSONALIZED MEDICINE TO AID GROWTH

12 EPIGENETICS MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 Strong network of well-established epigenetic product manufacturers to spur growth
    • 12.2.3 CANADA
      • 12.2.3.1 Favorable government initiatives to contribute to growth
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Significant investments in next-generation sequencing to bolster growth
    • 12.3.3 UK
      • 12.3.3.1 Rising acceptance of genome-based diagnostic techniques to support growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Growing demand for PCR technologies to drive market
    • 12.3.5 ITALY
      • 12.3.5.1 High incidence of cancer to expedite growth
    • 12.3.6 SPAIN
      • 12.3.6.1 Well-established network of research centers and universities to boost market
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 High demand for personalized medicine to accelerate growth
    • 12.4.3 JAPAN
      • 12.4.3.1 Increasing collaborations between research & academic organizations to favor growth
    • 12.4.4 INDIA
      • 12.4.4.1 Expanding base of biotechnology facilities to drive market
    • 12.4.5 AUSTRALIA
      • 12.4.5.1 Growing hub for epigenetics to propel market
    • 12.4.6 SOUTH KOREA
      • 12.4.6.1 Rising burden of chronic diseases to foster growth
    • 12.4.7 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Increasing number of healthcare providers incorporating epigenetic testing to aid growth
    • 12.5.3 MEXICO
      • 12.5.3.1 Growing adoption of cutting-edge technologies to drive market
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Saudi Arabia
        • 12.6.2.1.1 Growing healthcare expenditure to propel market
      • 12.6.2.2 UAE
        • 12.6.2.2.1 Increasing collaborations between public and private sectors to spur growth
      • 12.6.2.3 Rest of GCC countries
    • 12.6.3 REST OF MIDDLE EAST
  • 12.7 AFRICA
    • 12.7.1 RISING DEMAND FOR TARGETED THERAPIES TO AUGMENT GROWTH
    • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES
  • 13.3 REVENUE ANALYSIS
  • 13.4 MARKET SHARE ANALYSIS
  • 13.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.6 BRAND/PRODUCT COMPARISON
    • 13.6.1 THERMO FISHER SCIENTIFIC INC.
    • 13.6.2 ILLUMINA, INC.
    • 13.6.3 MERCK KGAA
    • 13.6.4 DANAHER
  • 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 13.7.1 STARS
    • 13.7.2 EMERGING LEADERS
    • 13.7.3 PERVASIVE PLAYERS
    • 13.7.4 PARTICIPANTS
    • 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 13.7.5.1 Company footprint
      • 13.7.5.2 Region footprint
      • 13.7.5.3 Offering footprint
      • 13.7.5.4 Method footprint
      • 13.7.5.5 Technology footprint
  • 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 13.8.1 PROGRESSIVE COMPANIES
    • 13.8.2 RESPONSIVE COMPANIES
    • 13.8.3 DYNAMIC COMPANIES
    • 13.8.4 STARTING BLOCKS
    • 13.8.5 COMPETITIVE BENCHMARKING
      • 13.8.5.1 Detailed list of key startups/SMEs
      • 13.8.5.2 Competitive benchmarking of key startups/SMEs
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY MARKET PLAYERS
    • 14.1.1 THERMO FISHER SCIENTIFIC INC.
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches
        • 14.1.1.3.2 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 ILLUMINA, INC.
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches
        • 14.1.2.3.2 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 MERCK KGAA
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 MnM view
        • 14.1.3.3.1 Key strengths
        • 14.1.3.3.2 Strategic choices
        • 14.1.3.3.3 Weaknesses and competitive threats
    • 14.1.4 PACBIO
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches
        • 14.1.4.3.2 Deals
        • 14.1.4.3.3 Expansions
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 DANAHER
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Deals
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 BIO-RAD LABORATORIES, INC.
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
    • 14.1.7 ACTIVE MOTIF
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Deals
    • 14.1.8 NEW ENGLAND BIOLABS
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches
        • 14.1.8.3.2 Deals
    • 14.1.9 QIAGEN
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Product launches
    • 14.1.10 ZYMO RESEARCH CORPORATION
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches
        • 14.1.10.3.2 Expansions
        • 14.1.10.3.3 Other developments
    • 14.1.11 REVVITY
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Deals
    • 14.1.12 HOLOGIC, INC.
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products offered
    • 14.1.13 F. HOFFMANN-LA ROCHE LTD
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products offered
    • 14.1.14 PROMEGA CORPORATION
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products offered
    • 14.1.15 EPIGENTEK GROUP INC.
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 EPICYPHER
    • 14.2.2 FIOS GENOMICS
    • 14.2.3 GENOMESCAN
    • 14.2.4 CREATIVE BIOGENE
    • 14.2.5 BPS BIOSCIENCE, INC.
    • 14.2.6 ABNOVA CORPORATION
    • 14.2.7 CREATIVE DIAGNOSTICS
    • 14.2.8 BIOMODAL
    • 14.2.9 INTEGRATED DNA TECHNOLOGIES, INC.
    • 14.2.10 NOVOGENE CO., LTD.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS